Summary
Owing to its ability to undergo one-electron reactions, iron transforms the mild oxidant hydrogen peroxide into hydroxyl radical, one of the most reactive species in nature. Deleterious effects of iron accumulation are dramatically evidenced in several neurodegenerative diseases. The work of Youdim and collaborators has been fundamental in describing the accumulation of iron confined to the substantia nigra (SN) in Parkinson’s disease (PD) and to clarify iron toxicity pathways and oxidative damage in dopaminergic neurons. Nevertheless, how the mechanisms involved in normal neuronal iron homeostasis are surpassed, remain largely undetermined. How nigral neurons survive or succumb to iron-induced oxidative stress are relevant questions both to know about the etiology of the disease and to design neuroprotective strategies. In this work, we review the components of neural iron homeostasis and we summarize evidence from recent studies aimed to unravel the molecular basis of iron accumulation and dyshomeostasis in PD.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Aguirre P, Mena N, Tapia V, Arredondo M, Núñez MT (2005) Iron homeostasis in neuronal cells: a role for IREG1. BMC Neurosci 6: 1–3
Alam ZI, Jenner A, Daniel SE, et al. (1997) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69: 1196–1203
Anderson GJ, Frazer DM, McKie AT, Vulpe CD (2002) The ceruloplasmin homolog hephaestin and the control of intestinal iron absorption. Blood Cells Mol Dis 29: 367–375
Arredondo M, Munñoz P, Mura CV, Núñez MT (2003) DMT1, a physiologically relevant apical Cu1+ transporter of intestinal cells. Am J Physiol Cell Physiol 284: 1525–1530
Berg D, Grote C, Rausch WD, Maurer M, Wesemann W, Riederer P, Becker G (1999) Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol 25: 901–904
Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC (1994) Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett 172: 151–154
Bouton C, Hirling H, Drapier JC (1997) Redox modulation of iron regulatory proteins by peroxynitrite. J Biol Chem 272: 19969–19975
Breuer W, Greenberg E, Cabantchik ZI (1997) Newly delivered transferring iron and oxidative cell injury. FEBS Lett 403: 213–219
Connor JR, Boeshore KL, Benkovic SA, Menzies SL (1994) Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res 37: 461–465
Devalia V, Carter K, Walker AP, Perkins SJ, Worwood M, May A, Dooley JS (2002) Autosomal dominant reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin 1 gene (SLC11A3). Blood 100: 695–697
Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 52: 1830–1836
Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira AH, et al. (1994) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 35: 38–44
Double KL, Gerlach M, Youdim MB, Riederer P (2000) Impaired iron homeostasis in Parkinson’s disease. J Neural Transm [Suppl 60]: 37–58
Eisenstein RS, Ross KL (2003) Novel roles for iron regulatory proteins in the adaptive response to iron deficiency. J Nutr 133: 1510S–1516S
Epsztejn S, Kakhlon O, Glickstein H, Breuer W, Cabantchik I (1997) Fluorescence analysis of the labile iron pool of mammalian cells. Anal Biochem 248: 31–40
Faucheux BA, Hauw JJ, Agid Y, Hirsch EC (1997) The density of [125I]-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson’s disease. Brain Res 749:170–174
Faucheux BA, Martin ME, Beaumont C, Hunot S, Hauw JJ, Agid Y, Hirsch EC (2002) Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson’s disease. J Neurochem 83: 320–330
Floor E, Wetzel MG (1997) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70: 268–275
Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63: 793–807
Good PF, Hsu A, Werner P, Perl DP, Olanow CW(1998) Protein nitration in Parkinson’s disease. J Neuropathol Exp Neurol 57: 338–342
Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA (1995) Increased iron-related MRI contrast in the substantia nigra in Parkinson’s disease. Neurology 45: 1138–1143
Gotz ME, Double K, Gerlach M, Youdim MB, Riederer P (2004) The relevance of iron in the pathogenesis of Parkinson’s disease. Ann NY Acad Sci 1012: 193–208
Grisoli M, Piperno A, Chiapparini L, Mariani R, Savoiardo M (2005) MR imaging of cerebral cortical involvement in aceruloplasminemia. Am J Neuroradiol 26: 657–661
Gunshin H, Mackenzie B, Berger UV, et al. (1997) Cloning and characterization of a proton-coupled mammalian metal ion transporter. Nature 388: 482–488
Guo B, Phillips JD, Yu Y, Leibold EA (1995) Iron regulates the intracellular degradation of iron regulatory protein 2 by the proteasome. J Biol Chem 270: 21645–21651
Gutteridge JM, Halliwell B (2000) Free radicals and antioxidants in the year 2000. A historical look to the future. Ann NY Acad Sci 899: 136–147
Hansen TM, Nielsen H, Bernth N, Moos T (1999) Expression of ferritin protein and subunit mRNAs in normal and iron deficient rat brain. Brain Res Mol Brain Res 65: 186–197
Hanson ES, Foot LM, Leibold EA (1999) Hypoxia post-translationally activates iron-regulatory protein 2. J Biol Chem 274: 5047–5052
Hauptmann N, Cadenas E (1997) The oxygen paradox: Biochemistry of active oxygen. In: Scandalios JG (ed) Oxidative stress and the molecular biology of antioxidant defenses. Cold Spring Harbor Laboratory Press, New York, pp 1–20
He Y, Thong PS, Lee T, Leong SK, Mao BY, Dong F, Watt F (2003) Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys. Free Radic Biol Med 35: 540–547
Hellman NE, Gitlin JD (2002) Ceruloplasmin metabolism and function. Annu Rev Nutr 22: 439–458
Henze C, Earl C, Sautter J, Schmidt N, Themann C, Hartmann A, Oertel WH (2005) Reactive oxidative and nitrogen species in the nigrostriatal system following striatal 6-hydroxydopamine lesion in rats. Brain Res 1052: 97–104
Hill JM, Ruff MR, Weber RJ, Pert CB (1985) Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to iron distribution. Proc Natl Acad Sci USA 82: 4553–4557
Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson’s disease: an X-ray microanalysis. J Neurochem 56: 446–451
Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP (2003) The role of glial reaction and inflammation in Parkinson’s disease. Ann NY Acad Sci 991: 214–228
Hubert N, Hentze MW (2002) Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: implications for regulation and cellular function. Proc Natl Acad Sci USA 99: 12345–12350
Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, Faucheux BA, Agid Y, Hirsch EC (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci USA 94: 7531–7536
Kakhlon O, Cabantchik ZI (2002) The labile iron pool: characterization, measurement, and participation in cellular processes. Free Radic Biol Med 33: 1037–1046
Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron 37: 899–909
Kim S, Ponka P (2002) Nitrogen monoxide-mediated control of ferritin synthesis: implications for macrophage iron homeostasis. Proc Natl Acad Sci USA 99: 12214–12219
Kruszewski M (2003) Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 531: 81–92
Latunde-Dada GO, Vulpe CD, Anderson GJ, Simpson RJ, McKie AT (2004) Tissue-specific changes in iron metabolism genes in mice following phenylhydrazine-induced haemolysis. Biochim Biophys Acta 690: 169–176
Ludwiczek S, Aigner E, Theurl I, Weiss G (2003) Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 101: 4148–4154
Martins EA, Robalinho RL, Meneghini R (1995) Oxidative stress induces activation of a cytosolic protein responsible for control of iron uptake. Arch Biochem Biophys 10: 128–134
McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, Miret S, Bomford A, Peters TJ, Farzaneh F, Hediger MA, Hentze MW, Simpson RJ (2000) A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 5: 299–309
McKie AT, Barrow D, Latunde-Dada GO, et al. (2001) An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 291: 1755–1759
McNaught KS, Olanow CW(2005) Protein aggregation in the pathogenesis of familial and sporadic Parkinson’s disease. Neurobiol: Epub ahead of print
Mehlhase J, Sandig G, Pantopoulos K, Grune T (2005) Oxidation-induced ferritin turnover in microglial cells: role of proteasome. Free Radic Biol Med 38: 276–285
Miyajima H, Takahashi Y, Kono S (2003) Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals 16: 205–213
Mogi M, Togari A, Tanaka K, Ogawa N, Ichinose H, Nagatsu T (1999) Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction. Neurosci Lett 268: 101–104
Nanami M, Ookawara T, Otaki Y, Ito K, Moriguchi R, Miyagawa K, Hasuike Y, Izumi M, Eguchi H, Suzuki K, Nakanishi T (2005) Tumor necrosis factor-alpha-induced iron sequestration and oxidative stress in human endothelial cells. Arterioscler Thromb Vasc Biol 25: 2495–2501
Núñez MT, Gaete V, Watkins JA, Glass J (1990) Mobilization of iron from endocytic vesicles: the effect of acidification and reduction. J Biol Chem 265: 6688–6692
Núñez MT, Gallardo V, Múñoz P, Tapia V, Esparza A, Salazar J, Speisky H (2004) Progressive iron accumulation induces a biphasic change in the glutathione content of neuroblastoma cells. Free Radic Biol Med 37: 953–960
Núñez-Millacura C, Tapia V, Múñoz P, Maccioni RB, Núñez MT (2002) An oxidative stress-mediated positive-feedback iron uptake loop in neuronal cells. J Neurochem 82: 240–248
Paradkar PN, Roth JA (2005) Post-translational and transcriptional regulation of DMT1 during P19 embryonic carcinoma cell differentiation by retinoic acid. Biochem J: Epub ahead of print
Patel BN, David S (1997) A novel glycophosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes. J Biol Chem 272: 20185–20190
Perry G, Taddeo MA, Petersen RB, Castellani RJ, Harris PLR, Siedlak SL, Cash AD, Liu Q, Nunomura A, Atwood CS, Smith MA (2003) Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. Biometals 16: 77–81
Petrat F, de Groot H, Sustmann R, Rauen U (2002) The chelatable iron pool in living cells: a methodically defined quantity. Biol Chem 383: 489–502
Reiber H, Ruff M, Uhr M (1993) Ascorbate concentration in human cerebrospinal fluid (CSF) and serum. Intrathecal accumulation and CSF flow rate. Clin Chim Acta 217: 163–173
Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515–520
Sayre LM, Perry G, Atwood CS, Smith MA (2000) The role of metals in neurodegenerative diseases. Cell Mol Biol 46: 731–741
Schalinske KL, Eisenstein RS (1996) Phosphorylation and activation of both iron regulatory proteins 1 and 2 in HL-60 cells. J Biol Chem 271: 7168–7176
Shoham S, Youdim MB (2002) The effects of iron deficiency and iron and zinc supplementation on rat hippocampus ferritin. J Neural Transm 109: 1241–1256
Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MB (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74: 199–205
Symons MCR, Gutteridge JMC eds (1998) Free radicals and iron: chemistry, biology and medicine. Oxford University Press, New York
Wang X, Garrick MD, Yang F, Dailey LA, Piantadosi CA, Ghio AJ (2005) TNF, IFN-gamma, and endotoxin increase expression of DMT1 in bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 289:L24–L33
Williams J, Moreton K (1980) The distribution of iron between the metalbinding sites of transferrin human serum. Biochem J 185: 483–488
Wu LJ, Leenders AG, Cooperman S, Meyron-Holtz E, Smith S, Land W, Tsai RY, Berger UV, Sheng ZH, Rouault TA (2004) Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier. Brain Res 1001: 108–117
Yang F, Haile DJ, Wang X, Dailey LA, Stonehuerner JG, Ghio AJ (2005) Apical location of ferroportin 1 in airway epithelia and its role in iron detoxification in the lung. Am J Physiol Lung Cell Mol Physiol 289: L14–L23
Youdim MB, Riederer P (1993) The role of iron in senescence of dopaminergic neurons in Parkinson’s disease. J Neural Transm [Suppl 40]: 57–67
Youdim MB, Stephenson G, Ben Shachar D (2004) Ironing iron out in Parkinson’s disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann NY Acad Sci 1012: 306–325
Youdim MB, Fridkin M, Zheng H (2005) Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev 126: 317–326
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag
About this chapter
Cite this chapter
Salazar, J., Mena, N., Núñez, M.T. (2006). Iron dyshomeostasis in Parkinson’s disease. In: Parvez, H., Riederer, P. (eds) Oxidative Stress and Neuroprotection. Journal of Neural Transmission. Supplementa, vol 71. Springer, Vienna. https://doi.org/10.1007/978-3-211-33328-0_22
Download citation
DOI: https://doi.org/10.1007/978-3-211-33328-0_22
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-33327-3
Online ISBN: 978-3-211-33328-0
eBook Packages: MedicineMedicine (R0)